After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
The companies hopes to be as efficacious as ex vivo therapy, with convenience and safety advantages.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
